Cor Vasa 2011, 53(10):579-582

Antagonisté aldosteronu / diuretika šetřící kalium. Renesance staré léčby srdeční insuficience - eplerenon

Dr. Med. Pavel Jerie

Published: October 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jerie P. Antagonisté aldosteronu / diuretika šetřící kalium. Renesance staré léčby srdeční insuficience - eplerenon. Cor Vasa. 2011;53(10):579-582.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J. Antagonisté aldosteronových receptorů v léčbě chronického selhání. Výsledky nové studie EMPHASIS. Cor Vasa 2011;53:112-117. Go to original source...
    2. Armstrong PW. Aldosterone antagonists - last man standing? N Engl J Med 2011;365:79-80. Go to original source... Go to PubMed...
    3. Parthasarathy HK, Ménard J, White WB, et al. A doble-blind randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypert 2011;29:980-990. Go to original source... Go to PubMed...
    4. Yano Y, Hoshide S, Tamaki N, et al. Efficacy of eplerenone added to renin-angiotensin blocade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. JRAAS 2011;20:1-8. Go to original source... Go to PubMed...
    5. Holaj R. Je spironolakton lékem volby u rezistentní hypertenze? In: Widimský J, jr., et al. Arteriální hypertenze - současné klinické trendy IX. Praha: Triton, 2011:57-62.
    6. Pascual-Fugal DA, Sanchez-Mas J, Gus M, et al. Eplerenone in mild heart failure. N Engl Med J 2011;364:1372-1374. (Letters to the Editor)
    7. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompesated heart failure. N Engl Med J 2011;364:797-805. Go to original source... Go to PubMed...
    8. Tonks A. New evidence exposes an old treatment. Brit Med K 2011;342:572.
    9. Pouleur H. Improving patient care: Some unresolved issues in heart failure. Cardiology 1994;84:408-412. Go to original source... Go to PubMed...
    10. McMahon FG. Management of essential hypertension. Mount Kisco, N.Y.: Futura Publ. Company, Inc., 1978:107-150.
    11. Zerkowski H-R, Baumann G. Herz Akut Medizin. Ein Manual für die kardiologische, herzchirurgische, anästhesiologische und internistische Praxis. II. Vydání. Darmstadt: Steinkopf Verlag, 1999:812 s.
    12. O'Rourke RA, Fuster V, Alexander RW (Eds.): Hurst's The Heart. Manual of cardiology. 11. vydání. New York: McGraw-Hill, 2004:684 s.
    13. kalvoda J, deGasparo M. Eplerenone: selective aldosteron antagonist. In: Fischer J, Gennelin CR (Eds.): Analogue-based drug discovery II. Weinheim: Willey-Vch Verlag, 2010:359-380. Go to original source... Go to PubMed...
    14. Jerie P. Kardiologie praktického lékaře. Praha: Státní zdrav. nakladatelství, 1964:354 s.
    15. Horký K, Küchel O. Užití spirolaktonu v terapii městnavé srdeční slabosti. Sborník lékařský 1963;65:209-220. Go to PubMed...
    16. Jerie P. Nové možnosti léčby otoků rezistentních na běžná diuretika. Poznámky k článku dr. Horkého a dr. Küchela. Prakt Lék 1967;47:901-905.
    17. Ascherman M, Horký K. Praktické aspekty moderní farmakoterapie hypertenze. Prakt Lék 1974;54:835-839.
    18. Brod J. The Kidney. Buttersworth and Co. Ltd. 1973:740.
    19. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1983;316:1429-1435. Go to original source... Go to PubMed...
    20. The Lancet Editorial. Consensus on heart failure management? Lancet 1987;316:311-312. Go to original source...
    21. Massie BM. 15 years of heart-failure trials: what have we learned? Lancet 1998;352(suppl 1):29-33. Go to original source... Go to PubMed...
    22. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341: 709-717. Go to original source... Go to PubMed...
    23. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 2005;26: 313-321. Go to original source... Go to PubMed...
    24. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in pacients with cognestive heart failure. Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2004;102:2700-2706. Go to original source... Go to PubMed...
    25. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. Go to original source... Go to PubMed...
    26. INSPRA. In: Arzneimittelkompendium der Schweiz 2011. Basel, Documed, 2011, s. 2462-2465.
    27. Vogt B, Waeber B, Burnier M. Eplerenon - ein selektiver Mineralokortikoid-Rezeptor-Antagonist. Schweiz Med Forum 2007;7:351-354. Go to original source...
    28. Zannad F, McMurray JJV, Krum H, et al., for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21. Go to original source... Go to PubMed...
    29. Eplerenon senkt das Risiko für Vorhofflimmern. Cardio News 2011;14:3.
    30. Charvát J. Život, adaptace a stres. Praha: Avicenum, 1973:153 s.
    31. Selye H. Protection by a steroid-spironolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med 1960;104:212-213. Go to original source...
    32. Widimský J, Cífková R. Hypertension and arryhytmias. Cor Vasa 1989;31: 157-163.
    33. Kasalová Z, jr., Horáková E, Zelinka T, Král J. Jakou hodnotu kalemie lze ještě přežít? Kap Kardiol 2004;6:147-148.
    34. Dent A, Walmsley D, Dhandapani S. Hyperkalaemia risk in vurnelable patients. Brit Med J 2011;343:d4514. (July 23, 2011, s. 172). Go to original source... Go to PubMed...
    35. Cort JH, Fencl V. Tělesné tekutiny. Praha: Státní zdravotnické nakladatelství, 1957:355 s.
    36. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol 2011; e-pub ahead of print.
    37. Deswal A, Richardson P, Bozkurt B, et al. Results of the Randomized Aldosterone Antagonists in heart failure with Preserved Ejection Fraction Trial (RAAM-PEF). J Cardiac Fail 2011;17:634-642. Go to original source... Go to PubMed...
    38. Jerie P. Milníky kardiovaskulární terapie. V. Diuretika. Čas Lék čes 2007;146: 858-861.

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes